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3,4-Dihydroxybenzylamine: An Improved Dopamine Analog Cytotoxic 
for Melanoma Cells in Part Through Oxidation Products Inhibitory to 
DNA Polymerase 
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The dopamine analog 3,4-dihydroxybenzylamine (3,4-
DHBA), a novel antitumor agent, was shown to inhibit 
directly DNA polymerase in cells of the deeply pig-
mented murine melanoma, S -91A, p ermeabilized to nu-
cleotides by lysolecithin. In contrast, levodopa and do-
pamine did not inhibit DNA polymerase in permeabilized 
cells in the absence of exogenous tyrosinase. Analysis 
using isolated DNA polymerase showed that the inhibi-
tory activity of the ortho dihydroxy compounds was 
totally d e p endent upon enzymatic activation. The enzy-
matic activation of the ortho derivative 3,4-DHBA by 
tyrosinase results in two reactive species: a semiquinone 
intermediate and a less reactive quinone. Inhibition of 
DNA polymet'ase by activated 3,4-DHBA was shown by 
dialysis and kinetic studies to involve an irreversible 
reaction which occurs at two inhibitor interaction sites 
as determined by a H ill plot analysis. Double-stranded 
DNA protected the enzyme from inhibition by 3,4-DHBA, 
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Abbreviations: 
3,4-DHBA: 3,4-dihyd.roxybenzylamine 
DTE: di thioeryt.hritol 
IC",,: concentration resulting in 50% inhibi tion of enzyme 
RT: reverse lranscl'iptase 
s uggesting that the inhibitory s ites are at or near the 
template-initiator binding site. 
Levodopa, dopamine, and the therapeutically superior ana-
log, 3,4-dihydroxybenzylamine (3,4-DHBA) have been shown 
to be effective ant itumor agents in a variety of experimental 
melanoma tumors [1-3]. Recently, preliminary studies have 
suggested that these agents ar e capable of inhibiting replication 
in huma n melanoma and are in a clinical trial [4,5]. 
The inj t ial studies with these drugs revealed that th ey in-
hjbi ted thymidine incorporation in vitro, while having minimal 
effects on RNA or protein synthesis [1,2]. It appeared that the 
immediate cellular effect of th ese catechols was a direct and 
selective inhibition of DNA synthesis. Further studies demon-
strated that these drugs, in the presence of th e polyphenol 
oxidase, tyrosinase (which catalyzes th e oxidation of tyrosine 
to melanin in melanocytes), are capable of inhibiting sulfhydryl-
dependen t DNA polymerases [3,4]. We have recently reported 
a detailed analysis with the sulfhydryl-dependent enzyme, re-
verse transcriptase (RT), which showed that active oxidation 
by tyrosinase produces a more reactive intermediate- semiqui-
none-than either the completely reduced or oxidized forms of 
3,4-DHBA [6]. The findings of Mason et al [7], and more 
recently, Felix and Sealy [8], which demonstrate by electron 
spin resonance that o-benzosemjquinones are formed by tyro-
sinase oxidation of catechols, support tllis concept of a llighly 
reactive intermediate inhibi tory species. 
We ,have extended our studies of the inhibitory action of 3,4-
DHBA to the enzym e, DNA polym erase 0 ', which is likely to be 
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a site of action of this agent within melanoma cells. Utilizing 
the ability of 3,4-DHBA to form a stable quinone, we have been 
able to make a direct comparison of the relative inhibitory 
activity of the semiquinone and quinone. We have also exam-
ined various aspects of th e mechanism of action of this drug 
toward DNA polymerase. Using permeabilized cells of the 
deeply pigmented S-91A murine melanoma, a heretofore unrec-
ognized structure-activity relationship within this class of di-
hydroxy compounds was detected with regard to their in vitro 
effect on DNA replication. These results supported the conten-
tion that 3,4-DHBA con'tains the minimum active structural 
moiety of this series and exhibits the greatest inhibitory activity 
toward DNA polymerase in vitro. 
MATERIALS AND METHODS 
Materials 
Radio labeled ['JH]-dTTP and ["H)-thymidine were purchased from 
New E ngland Nuclear, Boston, Massachusetts. Unlabeled deoxyribo-
nucleotide triphosphates were obtained from P-L Biochemicals, M il-
waukee, Wisconsin. Hydroq uinone was purchased from Merck and 
Company, Rahway, New Jersey. Adriamycin was obta ined from Adria 
Laboratories, Columbus, Ohio, and daunomycin was supplied by the 
National Cancer Institute, Bethesda, Maryland. 1,2-Benzoquinone was 
prepared immediately before use as described by Horner a nd Web.er 
(9). The analogs 3,4-dihydroxybenzylamine and N-acetyl dopam ine 
were prepared synthetical ly as has been described previously [10). Calf 
thymus DNA polymerase u was purchased from Worthington Diagnos-
tics, Freehold, New Jersey. Mushroom tyrosinase (ECl.14.18.l) (Sigma 
Chemical Company, St. Louis, Missouri) had a specific activity of 2,230 
units/mg solid. AU other drugs and enzymes used in this s tudy were 
obtained fTom Sigma. Poly(dA-dT) was pW'chased from Collaborative 
Research, Waltham, Massachusetts, a nd when used, the molar concen-
tration of poly(dA-dT) was based on the manufacturer's suggested 
molecular weight of approximately 200,000. All drug solu t ions were 
prepared immediately prior to use. 
Tn. Vitro Assay 
The origin and maintenance of Cloudman S-91A murine melanoma 
(ATCC, CCL 53.1) has been desc ribed [11]. This clone has been shown 
to have high levels of tyrosinase, enhanced I-dopa incorporation, and 
to be heavily pigmented, as compared to nonmela nocytes or amelanotic 
melanomas [11). Cells were maintained as monolayers in Fa lcon plastic 
nasks in McCoy's Medium 5A supplemented with 15% feta l calf serum, 
100 units of streptomycin, and 100 /lg penicillin / ml in 10% humidified 
ail' at 37.5°C. The techniques for radiolabeled precursor incorporation 
have been described prev iously [1). 
Permeabilized Cell Studies 
Analysis of ["H]-dTTP incorporation into S-91A was accomplished 
using cells permeabi lized by treatment with lysolecithin [12]. Exponen-
tially growing S-91A cells (5 x 10") were plated in 60- mm plastic Petri 
dishes and a llowed to grow for 48 hr. At th is time, the media was 
removed and cells were treated with lysolecith in (75 J.lg/ml for 2 min at 
4°C). Greater than 90% of the cells were permeabilized by this treat-
ment, as indicated by trypan blue exclusion. The permeabilized cells 
(5 x 10") were added to the DNA synthesis mixture and processed as 
described previously [12]. 
DNA Polymerase Assay 
In the standaJ'd DNA polymerase u assay, the following reagents . 
were added to give the indicated concentration in a final volume of 75 
J.ll: 20 mM potassium phosphate (pH 7.2); 1 mM MgCb; 50 f.LM ["H]-
dTTP (4 ,440 dpm/pmol); 100 J.lM of other complementary deoxyribo-
nucleotide triphosphate as prescribed by the particular template; and 
40 J.lg/ ml template a nd sufficient DNA polymerase a to give approxi-
mately 0.1 units of enzyme activity where 1 unit of enzyme incorporates 
1 nmol of ["H)-dTTP in to acid-insoluble material in 1 hr with poly(dA-
dT) as template. T he reaction mixture was incubated at 36°C for 30 
min, and 50-J.ll samples were applied to Whatman GF /C glass fiber discs 
that had been presoaked in 5% TCA and 2% sodium pyrophosphate. 
The discs were then processed as described previously [13], except that 
they were collected in 25% TCA-2% sodium pyrophosphate and washed 
in 10% TCA. In the standard inhibition assay, the drug was added 
immediately prior to the addit ion of DNA polymerase. Preincubation 
of the drug with tyrosinase was performed in 20 mM potassium phos-
phate (pH 6.8) at room temperature and diluted 10-fold in to the 
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reaction mixtme immedia tely before addition of DNA polymerase. The 
presence of tyrosinase at a final concentration of 100 J.lg/ ml had a 5-
10% stimulatory effect on DNA polymerase ac tivity. 
Dialysis 
All dia lysis was carried out using a microdialyzing apparatus (MRA 
Corporation, Clearwater , Florida). Samples (50-100 J.ll) were dialyzed 
40 hr with one change of buffer (600 ml) . All spectrophotometric 
measurements were perfOJ'med using a Cary model 15 spectrophotom-
eter . 
RESULTS 
Precursor IncOlporation Studies with S-91A 
Table I shows the effect of several dihydroxy compounds 
upon the incorporation of thymidine by S-91A, a deeply pig-
mented clone of melanoma cells. Significant inhibition of DNA 
synthesis was found with all of these compounds, although 
levodopa is the least effective of these drugs. 
The results presented in T able I also demonstrate the effect 
of several dihydroxy compounds on the incorporation of TTP 
by cells that were permeabilized by lysolecithin [12). This assay 
permits the direct examination of the effects of drugs upon the 
ultimate step in replication of DNA; i.e. , the incorporation of 
nucleotide triphosphates into the growing polynucleotide chain 
by DNA polymerase. The S-91A pigmented clone shows sig-
nificant inhibit ion of TTP incorporation following a I-hr expo-
sure to 3,4-DHBA. Levodopa, dopamine, and levodopa methyl 
ester, which inhibit DNA synthesis in intact cells (Table I), 
showed no inhibitory activity against DNA polymerase in per-
meabilized cells. N-acetyl dopamine has limited inhibi tory ac-
tivity as measmed by TTP incorporation. These results suggest 
that there are subtle structure-activity relationships among the 
dihydroxy compounds which have been previously masked due 
to the necessity of employing exogenous tyrosinase [12). 
Characterization of DNA Polymerase ex 
The replication of the copolymer , poly(dA-dT), exhibited a 
sha rp Mg:l+ optimum at 1 mM and was linear with time for a 
period of 30 min (data not shown) . Using the method described 
by Atkinson et al [14] to determine the interaction coefficient 
(n), the replication of DNA polymerase (~ was found to have 
first-order kinetics with respect to both template and monomer. 
The Hill plots (Fig 1) for both substrates have a slope (n) of 1, 
suggesting one binding site for each substrate per enzyme 
molecule. C,hang has used the Hill plot analysiG to obtain a 
similar resul t for the order of reaction with respect to reactants 
for polymerase f3 (DNA repair enzyme) using a homopolymer 
template [15). The DNA polymerase ex h ad a K", for the 
template poly(dA-dT) of 32 nm, and with this template, the K", 
for the monomer dTTP was found to be 12 P.M. 
Mechanism of Action of 3,4-DHBA: Tyrosinase Activation 
I n agreement with earlier studies, enzymatic oxidation of 
ortho catechols was found to be essential for inhibit ion of 
TABLE 1. E ffect of variollS analogs of levodopa and dopamine on 
{'H)-thymidine and ('H.1·TTP incorporation by the deeply 
pigmented S9J-A Cloudman melanoma cells" 
Drug % Inhibi t ion of lh ymi- % Inhibition of TTP din e incorporalion" incorpo ra lion" 
3,4-DHBA 90 74 
N-acetyl dopam ine 95 35 
Levodopa 41 0 
Dopamine 80 0 
Levoclopa methyl ester 87 0 
"Values are percent inhibition as compared to control at a drug 
concentration of 1 mM a nd represent the mean of triplicate samples. 
S.D. ± 5%. 
/, For these experiments, drug (1 mM) and ["H]-dThd were added 
simultaneously to exponentially growing cells and incubated for 60 min . 
,. Permeab ilized cells were treated for 15 min with the drug, followed 
by the addition of ["H]-dTTP and incubated for an addi t iona l 30 min. 
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FIG 1. Hill plots of calf thymus DNA polymerase o' reaction for 
template and monomer. T he reactions were carried out as described in 
the text, except that t he concentration of one reactant was held at a 
constant satw-ating level, while vary ing the concentra tion of the other 
reactant (X ), poly (dA-dT) (0 ), or dT T P (0 ). V is the init ial velocity 
and V,,, is the maximum velocity as calc!llated by a double reciprocal 
plot. 
replication, and addi tion of free sulfhydryl groups (i.e., 1 mM 
DTE) completely prevented the inhibitory activity [6,12]. A 
recen t study wi th RT demonstrated t hat the active inhibitor 
was the short-lived semiquinone intermediate [6]. T his conclu-
sion was based, in par t, on the fact that active oxidation was 
necessary for inhibi tion since preincubation of 3,4-DHBA (lO- r, 
M) with tyrosinase resul ted in complete loss of inhibitory activ-
ity. In the present study, we have been able to determine the 
extent of this loss or reduction in inhibitory activity following 
preincubation. Fig 2 clearly demonstrates an approximately 10-
fold decrease in inhibitory activity of 3,4-DHBA after 30 min 
preincubation with tyrosinase. Thus, at a low drug concentra-
tion (10-" M) , no inhibitory activity is observed following prein-
cubation, whereas without preincubation, this concentration is 
sufficient to cause almost total inhibition of polymerase activity. 
The quinone oxidation product, formed by preincubation 
with tyrosinase, is very stable as demonstra ted by spectroph o-
tometric measm ement, which revealed no change in the 385-
nm peak characteristic of this quinone [6]. T he stability of this 
quinone is attributed to its ina bili ty to undergo in tramolecular 
cyclization [3] and the fact that intermolecular dimerization of 
o-quinones is extremely slow at or below concentrations of 0.1 
mM [16]. 
These results suggest that tyrosinase generates a short-lived 
intermediate (semiquinone) which is a more highly reactive 
inhibitory species than the more stable quinone oxidation prod-
uct. Fmthermore, by using the H ill -type plot as described by 
Loft field and Eigner [17], the slopes of the lines of Fig 2 a re 
equivalent to the interaction coeffi cient of the inhibitor. These 
results suggest either tha t there ru'e two subuni ts inactivated or 
two inhibitor interaction sites per enzyme molecule. The latter 
conclusion is most likely, since results in Fig 1 indicate that the 
DNA polymerase has a single, independent active site. 
R eversibility S tudies 
Following a I-ill' expOSUl"e of DNA polymerase IX or t he 
template to either, 3,4-DHBA or adl"iamycin, which is known 
to act primarily upon the template [18], the inhibitors were 
r emoved by dialysis in an attempt to restore activi ty. Con trols 
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FI G 2. Hill -type plots of the inhibition polymerase a by 3,4-DHBA 
preincubated (0) or not preincubated (0; 6 ) with tyrosin ase. Preincu-
bation of the drug involved a 30-min exposw-e to tyrosinase as described 
in the text. Samples (with or without preincubation) were added to the 
st.andard inhibit ion assay mixture containing tyrosinase. Vo is the 
uninhibi ted reaction rate and V is the inhibited rate. 
TABLE II. R eversibility of inhibition of DNA replication after 
dialysis of temp late or DNA polymerase exposed to replication 
. inhibitors 
lnhibi t.o r 
Adriamycin 
Adl"iamycin 
34-DHBA" 
3:4-DHBA" 
Componen t 
Poly(dA-dT) 
DNA polymerase a 
Poly(dA-dT) 
DNA polymerase a 
["Hl·TMP (cpm) incor-
porated" 
194 (0.3) 
44,913 (96) 
39,253 (101) 
441 (4) 
" The various co mponents were pl"eincubated with Ol" without the 
drug (OJ mM) for 1 hI". T he samples were then dialyzed using a 
microdialysis apparatus. Following dialysis, the samples were assayed 
in a standard DNA polymel"ase mixture. Numbers in par entheses are 
percentage of control. 
"The samples (t.reated and un treated) were preincubated with ty-
rosinase (100 flg/ ml). 
indicated t hat the duration of dialysis was suffic ien t to reduce 
the concentration of drugs to less than 1 J..I.M. T he results (Table 
II) indicate that the site of action of 3,4-DHBA is the polym-
erase and that inhibition is not reversed by dialysis. Addition of 
DTE (lmM) to the dialyzed polymerase did not restore activity. 
In contrast, adriamycin had no effect on DNA polymerase. 
T emplate activi ty, however, was not restored following removal 
of adriamycin by dialysis, indicating an irreversible effect. 3,4-
DHBA did not have any effect upon the function of the tem-
plate. 
Tyrosinase-Activated 3,4-DHBA: Irreversible DNA 
Polymerase (y Inhibitor 
Another criterion for reversibili ty involves th e Ackermann 
and Potter graphic method [19] in which the velocity (V",,,xl is 
measw'ed as a ' function of enzyme concentration. Such an 
analysis, shown in Fig 3, was cru-ried out under reaction condi-
tions in which the substrate (template and monomers) were 
saturating so that the initial velocit ies approached V",,,x. At the 
lowest concentrations of enzyme, the activities of control and 
dnlg-treated samples were not propor tional to enzyme concen-
tration due to a dilut ion effect. Cory has demonstrated the 
applicabili ty of this method of determining reversibility of 
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FIG 3. P lot of the rate of replication vs. re lative DNA polym erase 
ex concentration in the presence and absence of 3,4·DHBA. Various 
dilutions of DNA polymerase ex containing tyrosinase were pre incu· 
bated in the absence of DNA with 3,4·DHBA 1 fLM (6 ) or without drug 
(0 ). Template, poly (dA·dT) , was then added to start the poly merase 
reaction. T he reaction was performed under conditions in which the 
template and monomer were satUl'ating, so the measured rate (V) 
approaches the maximum velocity (V"'). 
inhibition using enzymes that show a dilution effect [20]. Our 
results with DNA polymerase in the presence of tyrosinase· 
activated 3,4·DHBA show t hat the curve is shifted to the right 
so that a zero reaction velocity is reached at a n enzyme concen· 
trations >0, i.e., the inhibitor titrates out enzyme activity. Such 
a response would be expected for a n irreversible inhibitor [21]. 
Protection of Polymerase Against Activated 3,4·DHBA by 
the Template 
Preliminary preincubation experiments had suggested that 
the presence of DNA protected polymerase from tyrosinase· 
activated 3,4·DHBA (data not shown) . However, the DNA 
concentration utilized in these ini tial experiments gave only a 
mru'ginal degree of protection. We therefore repeated these 
experiments using 100 Ilg/ml template or 2.5 times the normal 
assay concentration of DNA. The results of preincubating 
polymerase with 3,4·DHBA indicate t hat the enzym e has 3 
times more remaining activity following preincubation in the 
presence of DNA than when the DNA is absent (Table III) . 
Similar experiments revealed that the monomer, dTTP, does 
not afford protection against activated 3,4·DHBA. 
Kinetics of Inhibition of DNA Polymerase ex by Activated 3,4· 
DHBA 
An Eadie·Hofstee plot of Vo (velocity) vs. Vo/So (substrate) 
at vru'ious template concentrations is shown in Fig 4. The 
results are consistent with a stoichiometric titration of the 
enzyme, although as demonstrated by Walter [22], different 
concentrations of a noncompetitive reversible inhibitor will also 
yield a similar set of linear plots having the same slopes, i.e., 
K", as the control withou t inhibitor. The results from the 
Ackermann·Potter plots (Fig 3), which showed the ilTeversible 
nature of th e inhibition, and th e data in Table III, which 
demonstrated that the template protects the enzyme (suggest· 
ing a competitive inhibitor), would argue that t he kinetic anal· 
ysis is indicative of stoichiometric, irreversible, competitive 
inhibition of DNA polymerase ex by 3,4·DHBA. 
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TABLE III. Protection of DNA polymerase ex from tyrosinase· 
activated 3,4·DHBA by DNA template 
["Hj.TMP (cpm) incorporated" 
3,4·DHBA (I'M) 
o 
5 
6 
7 
P re incubated without DNA 
30,000 (100)" 
2,250 (8.5) 
2,219 (7.4) 
1,793 (6.0) 
Preincubated with DNA 
34,894 (100)" 
10,005 (28.6) 
8,702 (24.9) 
6,809 (19.5) 
" Mean of duplicate samples (S.D. ± 5%). 
"Numbers in parentheses are percentage of control. 
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FIG 4. An Eadie·Hofstee plot of the inhibit ion of DNA polymerase 
Ci by tyrosinase·activated 3,4·DHBA. Various concentrations of tem· 
plate, poly (dA·dT), were used with an essentia lly standard DNA 
polymerase assay conta ining tyrosinase and saturatin g levels of t he 
monomers in the absence (6 ) and presence of 3,4·DHBA (4 .0 fLM [0 ] 
and 6.0 fLM [0]) . 
DISCUSSION 
The biologic effect of inhibitors of DNA synthesis can be 
assigned to one of two classes: (1) inhibition of the supply of 
deoxyribon ucleotides or (2) direct interference with polym erase 
reaction, either by inhibiting the polymerase enzyme or by 
altering the structm e of the initiator· template. Levodopa, do· 
pamine, and related dihydroxy compounds have been placed 
with t he latter class of inhibitors, based on the evidence that 
they are capable, in the presence of tyrosinase, of inhibit ing 
DNA synthesis in an isolated system by directly affecting the 
enzyme, DNA polym erase [12]. FLUthermore, a direct in vitro 
effect on DNA polymerase by these dl"ugs has been demon· 
strated with Iysolecithin·permeabilized ceUs in the presence of 
exogenous tyrosinase [12). 
This prior study utilized a hu man mela noma clone with light 
a nd variable pigm entation (a co rrelate of tyrosinase activity 
[11]), thus necessitating the addition of tyrosinase. We have 
now circumvented this problem with the deeply pigmented 
murine melanoma cell line, S·91A. Using such a system, it was 
possible to demonstrate that DNA polymerase can be directly 
inhibited in vitro by 3,4·DHBA, a nd to a lesser extent, by N· 
acetyl dopamine, but not by levodopa, dopamine, or levodopa 
methyl ester. The inhibition of DNA synt hesis in vitro by these 
latter three drugs must, therefore, primarily occur at a penul· 
t imate step in DNA synthesis, i.e., th e supply of deoxyribonu· 
cleotides (dNTPs). After completion of the present investiga. 
tion, we became awru'e of a recent study by Elford [23] which 
demonstrated that reduced polyhydroxybenzene derivatives, 
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including th e 5 levodopa analogs listed in Table I, are potent 
inhibitors of isolated ribonucleotide reductase, the key enzyme 
in the synthesis of dNTPs [24]. Ow- results with permeabilized 
cells may be interpreted as indirect evidence for the in vitro 
inhibition of riboreductase by levodopa analogs. We m·e pres-
ently pw-suing a study utilizing this system to examine directly 
the effect of t hese drugs on this enzyme in vitro. 
The dihydJ·oxy compounds can be classified into one of two 
categories accordin g to their principal site of action in pig-
mented melanoma cells: (1) inhibitors of DNA polymerase 0', 
e.g., 3,4-DHBA, and (2) t hose which limit the supply of deoxy-
ribonucleotides, inhibitors of ribonucleotide reductase, e.g., lev-
odopa. While these results do not rule out the possibility that 
levodopa may have some effect on polymerase or that 3,4-
DHBA may have additional effects, it is clear that in cells that 
do contain endogenous tyrosinase, the a nalog 3,4-DHBA is the 
superior inhibitor of DNA synthesis at the polymerase level. 
The exact structw-al featw-es responsible for t his differential 
response are unknown. Since levodopa and dopamine inhibit 
polymerase in th e presence of exogenous tyrosinase [12], it 
seems that the rate of oxidation is a critical factor in their 
inabili ty to inhibit polymerase in the S-91A permeabilized cell 
system. Indeed, as Elford 's [23] results suggest, oxidation may 
not be involved in the inhibition of DNA synthesis by levodopa 
or dopamine, but t he reduced catechol itself may be inhibi tory. 
The present analysis of the inhibitory activity of 3,4-DHBA 
toward DNA polymerase confirmed the requiJ·ement for enzy-
matic activation of the ortho derivatives. While ow- em·lier 
study demonstrated that inhibition of RT by enzyme-activated 
3,4-DHBA involved an intermediate species (semiquinone 
[6]), this report has quantitated the differential inhibitory ac-
t ivity between the stable, slower-reacting qu inone product and 
the less stable, fast-reacting semiquinone intermediate. The 
preincubation experiment (Fig 2) indicates a consistent lO-fold 
difference in DNA polymerase inhibitory activity between 3,4-
DHBA preincubated with tYl·osinase (quinone) and the drug 
without preincubation (semiquinone). 
The molecular mechanism for the inhibitory activity of ty-
rosinase-activated 3,4-DHBA is suggested by three basic obser-
vations. FiJ·st, th e various findings (e.g. , preincubation, dialysis, 
and kinetic studies) confiJ·m that the inhibition of replication 
by 3,4-DHBA occw-s at the level of DNA polymerase enzyme. 
This observation is extended by the Hill plot analysis which 
shows that there a re two inhibitor sites involved in the inacti-
vation of the enzyme. Secondly, the inhibition of polymerase 0' 
by tyrosinase-activated 3,4-DHBA is irreversible and cannot be 
restored by removal of the drug a nd addition of a reducing 
agent (e.g., DTE). This result, along with the demonstration 
that 3,4-DHBA titrates t he enzyme by reacting stoichiometri-
cally, suggests that the inactivation involves the formation of a 
covalent bond, possibly via a Michael add it ion of SH groups to 
the semiquinone species of 3,4-DHBA. While earlier work sug-
gested that inactivation of polymerase by quinols may be me-
diated by superoxide and hydJ"Oxyl-free radicals, it now appears 
more likely t hat inactivation is the result of diJ·ect titration of 
the enzyme by the dJ·ug and not a simple indiJ·ect oxidation. 
Lastly, DNA template protects the enzyme, suggesting that the 
site of inhibition is at or near the active site. 
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